The hypothesis that antidepressant response has a relevant genetic component was initially suggested by the observation that this phenotype clusters in families.
This study aimed to assess the attitudes and opinions of clinicians practicing in psychiatry toward pharmacogenomic testing, and in so doing elicits possible barriers and risks to employ this technology in patient care.
Promising pharmacogenetic targets for treating alcohol use disorder: evidence from preclinical models
This review explores promising novel genetic variants derived from preclinical models of alcohol consumption and dependence, and identifies novel pharmacogenetic targets that facilitate therapeutic intervention for the treatment of alcohol use disorder.
This Editorial article provides an insight into how pharmacogenomics can assist in guided dosing of fentanyl for the treatment of pain.
Pharmacoepigenetics of the role of DNA methylation in μ-opioid receptor expression in different human brain regions
In the study, the authors investigated a possible association between differential μ-opioid receptor expression across several brain areas and varying degrees of OPRM1 DNA methylation.
Identifying genetic loci affecting antidepressant drug response in depression using drug–gene interaction models
In this review, the researchers discuss the methodological challenges and limitations of the studies that have been conducted on this topic to date (e.g., ‘treated-only design’, statistical power) and discuss how specifically drug–gene interaction models can be used to be better able to identify genetic variants associated with antidepressant drug response in depression.
Influence of acylpeptide hydrolase polymorphisms on valproic acid level in Chinese epilepsy patients
In this research article, the authors determine the the effect of APEH polymorphism on VPA pharmacokinetics in the Chinese population.
This study investigated the influence of HLA class-I and -II genes in the response to IFN-β in relapsing-remitting multiple sclerosis (MS) patients.
The authors describe pharmacogenetic considerations for Alzheimer’s treatments, including for novel strategies such as epigenetic and combination therapies.
This review provides an overview of the potential role of pharmacogenomics in predisposing a child to unhealthy weight gain and cardiometabolic side effects with SGA treatment.